Welcome, Guest. Please login or register.
January 20, 2018, 04:12:35 PM

Login with username, password and session length

  • Total Members: 32184
  • Latest: timoup
  • Total Posts: 725317
  • Total Topics: 59123
  • Online Today: 311
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 4
Guests: 243
Total: 247


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Therapeutic Vaccine potential  (Read 3089 times)

0 Members and 1 Guest are viewing this topic.

Offline veritas

  • Member
  • Posts: 1,410
Therapeutic Vaccine potential
« on: May 26, 2009, 10:31:19 AM »


"This pre-clinical research partnership will combine the complementary technologies of DepoVax(TM) and GTU(R) MultiHIV. Both IVT and FIT Biotech will examine the novel vaccine's capabilities of inducing cell-mediated and humoral immunity against HIV virus"

Very preliminary.


Offline YellowFever

  • Member
  • Posts: 172
Re: Therapeutic Vaccine potential
« Reply #1 on: January 01, 2014, 04:31:09 PM »
I *think* this news update is related to the same technology. But feel free to start another thread:
Finnish company FIT Biotech has developed a vaccine to be tested in a large clinical trial. Hundreds of HIV patients will participate in the comprehensive study, which is scheduled to begin next year.

08/2010 HIV- 08/2012 HIV+
10/2012 CD4 415
04/2013 CD4 457
10/2013 CD4 520 VL 650
02/2014 CD4 410 VL 390
08/2014 CD4 580
01/2015 CD4 500 VL UD
05/2015 CD4 420 VL 2500
08/2015 CD4 460 VL UD
03/2016 CD4 500 VL UD
08/2016 CD4 410 VL 4467

Offline Jmarksto

  • Member
  • Posts: 655
Re: Therapeutic Vaccine potential
« Reply #2 on: January 02, 2014, 03:04:52 AM »
It looks like FIT Biotech has been at this for a while, with trials back to 2002 or so although the results on their website are sparse. Here is a Phase II study with results from 2012.


BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide immunological support to slow disease progression and decrease transmission. We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU()-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate.

METHODS:63 untreated, healthy, HIV-1 infected, adults between 18 and 40 years were enrolled in a single-blinded, placebo-controlled Phase II trial in South Africa. Subjects were HIV-1 subtype C infected, had never received antiretrovirals, with CD4 ≥ 350 cells/mm(3) and pHIV-RNA ≥ 50 copies/mL at screening. Subjects were allocated to vaccine or placebo groups in a 2:1 ratio either administered intradermally (ID) (0.5mg/dose) or intramuscularly (IM) (1mg/dose) at 0, 4 and 12 weeks boosted at 76 and 80 weeks with 1mg/dose (ID) and 2mg/dose (IM), respectively. Safety was assessed by adverse event monitoring and immunogenicity by HIV-1-specific CD4+ and CD8+ T-cells using intracellular cytokine staining (ICS), pHIV-RNA and CD4 counts.

RESULTS:Vaccine was safe and well tolerated with no vaccine related serious adverse events. Significant declines in log pHIV-RNA (p=0.012) and increases in CD4+ T cell counts (p=0.066) were observed in the vaccine group compared to placebo, more pronounced after IM administration and in some HLA haplotypes (B*5703) maintained for 17 months after the final immunisation.

CONCLUSIONS:The GTU()-multi-HIVB plasmid recombinant DNA therapeutic HIV-1 vaccine is safe, well tolerated and favourably affects pHIV-RNA and CD4 counts in untreated HIV-1 infected individuals after IM administration in subjects with HLA B*57, B*8101 and B*5801 haplotypes

A few things about this study:

1. It looks like the vaccine was focused on the subtype B, but tested on subjects with subtype C - perhaps someone can help explain that.

2. It would be good to see more quantitative results in terms of how much of a viral reduction, and CD4 increase there was - the P values only say that the results were statistically significant.
03/15/12 Negative
06/15/12 Positive
07/11/12 CD4 790          VL 4,000
08/06/12 CD4 816/38%   VL 49,300
08/20/12 Started Complera
11/06/12 CD4   819/41% VL 38
02/11/13 CD4   935/41% VL UD
06/06/13 CD4   816/41% VL UD
10/28/13 CD4 1131/45% VL 25
02/25/14 CD4   792/37% VL UD
07/09/14 CD4 1004/39% VL UD
11/03/14 CD4   711/34% VL UD
03/13/15 CD4   833/36% VL UD
04/??/15 Truvada & Tivicay
06/01/15 CD4 1100/50% VL UD
10/16/15 CD4   826/43% VL UD

Offline Dr.Strangelove

  • Member
  • Posts: 215
Re: Therapeutic Vaccine potential
« Reply #3 on: January 02, 2014, 10:43:13 AM »
Here's a 2010 article in Nature that mentions FIT Biotech's vaccine:

The FIT vaccine comprises a combination of gene fragments designed to make the patient immune to six viral proteins. In around 80% of patients receiving treatment, the virus was suppressed and CD4+ levels were maintained two years after therapy began.

Sounds promising, no?


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.